Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 6/20 | 0.43 |
| ▸ | IDH2 | P48735 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102609 | 1.00 | KCNH3 (0.50) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL15094951 | 0.86 | KCNH3 (0.50) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL29560969 | 0.86 | KCNH3 (0.50) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL16388487 | 0.83 | NPSR1 (0.45) | TSHRHSD17B10IDH2RORC | |
| SCHEMBL16392147 | 0.83 | ABCG2 (0.50) | NPC1TSHRHSD17B10IDH2 | |
| SCHEMBL18520669 | 0.83 | KCNH3 (0.47) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL15094829 | 0.81 | CTSK (0.51) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL15102579 | 0.80 | KCNH3 (0.67) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL29561752 | 0.80 | KCNH3 (0.67) | KCNH3NPC1TSHRHSD17B10IDH1 | |
| SCHEMBL15102288 | 0.78 | KCNH3 (0.58) | KCNH3NPC1TSHRHSD17B10IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647076-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier (FR) | 2025-11-12 | — | — | EP | disclosed |
| EP-3984997-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER LAB (FR) | 2025-07-30 | — | — | EP | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-03 | — | — | US | disclosed |
| CN-108912066-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | KCNH3 4722/4885NPC1 513/4885TSHR 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.